STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABVX
  4. [6-K] Abivax S.A. Current Report (Foreign Issuer)

Abivax (NASDAQ: ABVX) schedules May 11 general meeting in Paris

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Abivax SA has scheduled its annual ordinary and extraordinary general meeting for May 11, 2026, at 3:00 pm CEST in Paris. The company states that the agenda, draft resolutions and details on how to attend and vote were published in the French official legal bulletin on April 3, 2026. Preparatory documents required under French law are available to shareholders through the company’s website. This report and the attached press release are also incorporated by reference into Abivax’s existing Form F-3 and Form S-8 registration statements in the United States.

Positive

  • None.

Negative

  • None.
General meeting date May 11, 2026 Annual ordinary and extraordinary general meeting
Meeting time 3:00 pm CEST Scheduled start time of the general meeting
BALO notice date April 3, 2026 Publication date of preliminary notice and draft resolutions
ordinary and extraordinary general meeting financial
"informs its shareholders that its ordinary and extraordinary general meeting (the “General Meeting”) will be held"
Bulletin des Annonces Légales Obligatoires (BALO) regulatory
"was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 3, 2026"
Article R.22-10-23 of the French Commercial Code regulatory
"The documents referred to in Article R.22-10-23 of the French Commercial Code are available"
Phase 3 clinical trials medical
"obefazimod (ABX464), is in Phase 3 clinical trials for the treatment"
Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.
ulcerative colitis medical
"Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis"
A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.
Form 6-K: How Foreign Companies Report to the SEC →
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission File Number: 001-41842
Abivax SA
(Translation of registrant’s name into English)
7-11 boulevard Haussmann
75009 Paris, France
+33 (0) 1 53 83 08 41
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-
F.
Form 20-F [ X ] Form 40-F [ ]
On April 20, 2026, Abivax SA (the “Registrant”) published a press release entitled “Annual Ordinary and
Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents.” A copy of the press
release is filed as Exhibit 99.1 to this Report on Form 6-K and is incorporated herein by reference.
The inclusion of any website address herein, including in any exhibit attached hereto, is intended to be an inactive
textual reference only and not an active hyperlink. The information contained in, or that can be accessed through,
such website is not part of this Form 6-K nor is it incorporated herein.
Incorporation by Reference
This Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the
Registrant’s registration statements on Form F-3 (File No. 333-283336 and 333-288884) and Form S-8 (File No.
333-286069 and 333-294544) and to be part thereof from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed.
Exhibit Index
Exhibit 99.1
Press release, dated April 20, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Abivax SA
(Registrant)
Date: April 20, 2026
/s/ Marc de Garidel
Marc de Garidel
Chief Executive Officer

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026
Availability of the Preparatory Documents

PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting (the “General Meeting”) will be held on May 11, 2026, at 3:00 pm (CEST), at the hotel Paris Marriott Opera Ambassador, located at 16 boulevard Haussmann in Paris (75009), France.

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 3, 2026 (N°2600756).

The information and preparatory documents for this General Meeting are made available to the Company’s shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company’s website: www.abivax.com

About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878


Source: View Original Filing on SEC EDGAR

FAQ

When will Abivax (ABVX) hold its 2026 annual general meeting?

Abivax will hold its annual ordinary and extraordinary general meeting on May 11, 2026, at 3:00 pm CEST. The meeting will take place at the Paris Marriott Opera Ambassador hotel, 16 boulevard Haussmann, in Paris, France, for all eligible shareholders.

Where can Abivax (ABVX) shareholders find the preparatory documents for the 2026 general meeting?

Abivax states that the preparatory documents required under Article R.22-10-23 of the French Commercial Code are available on its website, www.abivax.com. These materials include information to help shareholders understand the agenda and proposed resolutions before voting.

What information about the Abivax (ABVX) general meeting was published in BALO?

Abivax explains that the preliminary notice of meeting, including the agenda, draft resolutions, and details on attending and voting, was published in the Bulletin des Annonces Légales Obligatoires on April 3, 2026, under number 2600756 as part of standard French legal requirements.

How does this Abivax (ABVX) 6-K relate to its U.S. registration statements?

Abivax indicates that this Form 6-K, including the attached press release, is incorporated by reference into its Form F-3 and Form S-8 registration statements. This means the meeting-related information becomes part of those U.S. securities registration documents from the filing date.

What business focus does Abivax (ABVX) highlight in this communication?

Abivax describes itself as a clinical-stage biotechnology company developing therapies that harness natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead candidate, obefazimod (ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis.

Who is the investor relations contact for Abivax (ABVX) regarding the 2026 general meeting?

Abivax lists Patrick Malloy as SVP, Investor Relations, with email patrick.malloy@abivax.com and phone +1 847 987 4878. Shareholders can use these contact details for questions related to the general meeting or broader investor information about the company.

Filing Exhibits & Attachments

1 document

Press Releases